Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry (ISACS-STEMI)

International Study on Acute Coronary Syndromes - ST-segment Elevation Myocardial Infarction COVID 19

The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.

Study Overview

Detailed Description

This is a retrospective multicenter registry including at least 40 European primary PCI centers with > 120 primary PCI/year (with expected average > 10/month), with the case load of STEMI not expected to be affected by a potential planned reorganization of the STEMI network. The inclusion period will be of 2 months (from March 1st until April 30th). The data will be compared with those retrospectively collected in the same time window of 2019.

Inclusion criteria: STEMI treated by primary angioplasty. Primary study outcome: Number of STEMI patients undergoing primary angioplasty. Secondary study outcomes: Ischemia time and the number of late presenters (> 12 hours from symptoms onset); 3) Door-to-balloon time and the number of patients with a DTB > 30 minutes); 4) In-Hospital mortality.

Data Collection: Data will be collected anonymized through a dedicated CRF. Each center will identify a local Principal Investigator. We will collect information on the study center, demographic, clinical, procedural data. Furthermore, we will collect data on total ischemia time, door-to-balloon time, type of access to the emergency system, COVID positivity, PCI procedure, data on in-hospital mortality.

Study Type

Observational

Enrollment (Actual)

6609

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Novara, Italy, 28100
        • Giuseppe De Luca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

STEMI Patients undergoing mechanical reperfusion

Description

Inclusion Criteria: STEMI Patients undergoing mechanical reperfusion

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
STEMI patients treated in March April 2019
Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
Percutaneous Mechanical Reperfusion for STEMI
Other Names:
  • Primary angioplasty
STEMI patients treated in March April 2020
Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
Percutaneous Mechanical Reperfusion for STEMI
Other Names:
  • Primary angioplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients undergoing primary angioplasty
Time Frame: March April 2019 and 2020
Number of patients undergoing primary angioplasty
March April 2019 and 2020
Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;
Time Frame: March April 2019 and 2020
Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
March April 2019 and 2020
Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Time Frame: March April 2019 and 2020
Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
March April 2019 and 2020
In-hospital mortality
Time Frame: March April 2019 and 2020
In-Hospital mortality
March April 2019 and 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 5, 2020

Primary Completion (ACTUAL)

May 30, 2020

Study Completion (ANTICIPATED)

June 2, 2020

Study Registration Dates

First Submitted

June 1, 2020

First Submitted That Met QC Criteria

June 1, 2020

First Posted (ACTUAL)

June 2, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 11, 2020

Last Update Submitted That Met QC Criteria

June 10, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion

Clinical Trials on Percutaneous Coronary Revascularization for STEMI

3
Subscribe